New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer’s annual meeting Nov. 9-14, including: Bergenbio, Exuma, Genexine, I-Mab, Imcheck, Innovent, Intensity, Jounce, Nektar, Shattuck, Sotio.